Brokerages Set Cresco Labs Inc. (OTCMKTS:CRLBF) Price Target at $2.50

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $2.50.

Several analysts have recently commented on the stock. Roth Capital raised shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Atb Cap Markets cut shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Finally, Cormark lowered shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th.

Cresco Labs Trading Down 4.2 %

OTCMKTS CRLBF opened at $0.97 on Tuesday. Cresco Labs has a one year low of $0.78 and a one year high of $2.65. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39. The business has a 50 day simple moving average of $1.09 and a 200 day simple moving average of $1.45. The stock has a market capitalization of $472.18 million, a P/E ratio of -4.84 and a beta of 1.79.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.